TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Eating Disorder symptomatology: drive for thinness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eating Disorder symptomatology: body dissatisfaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of adenosine diphosphate-induced platelet aggregation at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline of platelet activating factor-induced platelet aggregation at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in tissue plasminogen activator activity at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in plasminogen activator inhibitor-1 activity at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in visual status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of C3 dominant glomerulonephritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Inpatient Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Serum Choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of UACR testing order
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nerve growth factor (NGF) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurofilament light chain (NfL) protein Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dimensional accuracy of intraoral scanners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to a higher stage of AKI
Endpoint domain: Mortality/survival
Primary endpoint: Dialysis
Endpoint domain: Mortality/survival
Primary endpoint: Difference in stool microbiome pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (AE) of fecal microbiota transplantation (FMT)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Standard Uptake Value Ratios (SUVR) on FBB-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in CGA-NPI Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in K-MMSE Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in SNSB Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perception of Stress Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of treatment-related immune cells in the FNA sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of treatment-related immune cells in the blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change (%) in acetoacetate, total ketone, beta-hydroxybutyric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change (%) in LV mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Lack of flow or closed great saphenous vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ureteral obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Treatment Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Acceptability as Measured by Helping Alliance Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Acceptability as Measured by Therapy Suitability and Patient Expectancy questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Integration of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Volume reduction ratio (VRR) of the first ablated nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Natural Killer Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to treatment guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentrations of PAHs in women's visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated doses of natural killer (NK) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunstrom Hemiplegia Recovery Stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity of self-samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in concentration of plasma metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in severity of NAFLD as determined by elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in severity of NAFLD as determined by magnetic resonance spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in severity of NAFLD as determined by liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual-Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pao2/FIO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: predicted AV access choices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores (Visual analogue scores-VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nitrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective Sleep - Sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fine motor skills assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint range of motion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis after 2 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing financial difficulty
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change from baseline in bodyweight & BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ease of use and satisfaction with the mHealth App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Jaw mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Immunochemical Test Sensitivity and Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of biomarkers of translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attentional Intensity Index composite factor score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in atrophic acne scars assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Refractive error correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daytime ambulatory systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in nighttime ambulatory systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in office systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5D-ASC total OAV score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS good effect rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fugl Meyer Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Columbia Suicide Severity Rating Scale (C-SSRS) Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toronto Alexithymia Scale (TAS-20) Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Provision of Social Relations Scale (PSRS) Change
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Response to teclistamab at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live birth rate after the first embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: 3-yr bNED survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in the bend of the erect penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acromiohumeral distance (AHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with monogenic germline variants identifiable with WES sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of gHFI variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic yield for monogenic germline variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline of pain intensity on the Numerical Rating Scale at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in questioning pain-related disability from low back pain on the Roland Morris Disability Questionnaire at 3 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in assessing overall quality of Sleep at 3 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Noninvasive HVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with bone union achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in Standing Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Autonomic Nervous System Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Functional Connectivity of Neural Networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Task-Dependent Neural Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of foreign body ingestions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cancer-specific Survival
Endpoint domain: Mortality/survival
Primary endpoint: Ecological Footprint Awareness Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain relief during peri-operative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for QoL therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in 24-hour ambulatory SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 24-hour ambulatory DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Heart Failure with preserved ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of small fiber neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in threshold motor evoked potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in supramaximal motor evoked potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor evoked potentials (MEP) facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measurement of separation between the two-rectus abdominis muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of trunk flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of static trunk flexion endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with complete response by PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Days of postoperative hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of insertions of the needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of redirections of the needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of Kinesiological Tape Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial dysfunction measured by FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gas and/or stool incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fusion time of bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Endometriosis Health Profile (EHP-30) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Response Rate (ORR) As Assessed by the Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Self-Sufficiency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Total number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Bleeding Academic Research Consortium (BARC) type 2, 3 or 5
Endpoint domain: Adverse events/effects
Primary endpoint: Practical and social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Barriers for participation in society
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Facilitators for participation in society
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of subjects with complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of post-sclerotherapy hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Catch angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MACE-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in symptoms of voiding dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in the ADAS-cog/12 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in ADCS-ADL23 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cumulative incidence of aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardio-metabolic derangement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time above range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event and adverse drug reaction incidence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically-relevant changes in vital signs, physical exam, and laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Frailty Scale (CFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Laboratory aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cognitive function: attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in cognitive function: memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Region-level correct localization rate (CLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-level positive predictive value (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Efficacy (VE) of mRNA-1345 to Prevent a First Episode of RSV-LRTD with 2 or More Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio (GMR) of Serum RSV-A and RSV-B Neutralizing Antibodies After BD Compared to After Initial Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-reported carried weight at follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of self-reported safe lifting techniques during performance at follow up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of Contact Lens Related Ocular Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of Corneal epithelial Defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ocular hypertension greater than 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Cerebral Blood Flow from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in MADRS from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of diagnosing ADHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of diagnosing pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent use of EMT Strategies
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Maximum Observed Post Dose Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon isotope values from blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (ORR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penn Computerized Neuropsychological Testing System (Penn CNP) Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensory grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline of enlarged pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Progression of COVID-19 clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving IGA of clear (0) or almost clear (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant changes in Hemoglobin (g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in HAQ-2 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in serum C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anxiety reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hepatic and renal tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and immunogenicity of Hualan Biovar quadrivalent influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Rare adverse drug reaction (ADR) of 1‰
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of GeneXpert method for TB diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of nocturnal hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in PAD biomarker levels following exercise therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PAD biomarker levels following endovascular intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes